Cell & Gene Therapies

(Image: Getty/vchal)

Catalent bolsters Paragon through Novavax deal

By Vassia Barba

Aiming to boost the gene therapy development and manufacturing capabilities of Paragon, which Catalent acquired in April, the CDMO has agreed to acquire all of the gene therapy-related assets from Novavax, a late-stage vaccine developer.

(Image: Getty/BrianAJackson)

Hired and Retired: The knock-on effect

By Ben Hargreaves & Maggie Lynch

BMS’ capture of Celgene caught much attention, due to the size and scale of the acqusition, but rival companies have taken the chance to snap up employees that have left after the deal.

Follow us

Products

View more

Webinars